Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: stem cell-based therapeutics - Pluri

Drug Profile

Research programme: stem cell-based therapeutics - Pluri

Alternative Names: Placenta expanded mesenchymal cells; Placental-derived mesenchymal stem cells; PLX-BMP; PLX-BMT; PLX-I; PLX-IBD; PLX-Immune; PLX-MS; PLX-ORTHO; PLX-PAH; PLX-STROKE

Latest Information Update: 13 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pluristem Life Systems
  • Developer Berlin-Brandenburg Center for Regenerative Therapies; Hebrew University of Jerusalem; New York University School of Medicine; Pluri; Texas A&M University; United Therapeutics Corporation
  • Class Analgesics; Anti-inflammatories; Cardiovascular therapies; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Dopaminergic cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Diabetic foot; Diastolic heart failure; Haematological malignancies; Inflammatory bowel diseases; Multiple sclerosis; Musculoskeletal disorders; Myocardial infarction; Neuropathic pain; Pain; Parkinson's disease; Preeclampsia; Pulmonary arterial hypertension; Pulmonary fibrosis; Stroke

Most Recent Events

  • 28 Aug 2021 No recent reports of development identified for preclinical development in Cancer in Israel (IM, Injection)
  • 28 Feb 2020 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany (IM)
  • 28 Feb 2020 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in Israel (IM, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top